Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Altered within- and between-network functional connectivity in atypical Alzheimer’s disease
Singh, Neha Atulkumar , Martin, Peter R. , Graff‐Radford, Jonathan , Sintini, Irene , Duffy, Joseph R. , Gunter, Jeffrey L. , Botha, Hugo , Jones, David T. , Lowe, Val J. , Jack, Clifford R. , Josephs, Keith A. , Whitwell, Jennifer L. , Duffy, Joseph R , Botha, Hugo , Jones, David T , Jack, Clifford R , Josephs, Keith A , Whitwell, Jennifer , Singh, Neha Atulkumar , Machulda, Mary M.

Mayo Clinic

Brain Communications | June 14, 2023 | Volume: 5 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcad184 | PMID 37434879 Get It

Abstract Posterior cortical atrophy and logopenic progressive aphasia are atypical clinical presentations of Alzheimer’s disease. Resting-state functional connectivity studies have shown functional network disruptions in both phenotypes, particularly involving the language network in logopenic progressive aphasia and the visual network in posterior cortical atrophy. However, little is known about how connectivity differs both within and between brain networks in these atypical Alzheimer’s disease phenotypes. A cohort of 144 patients was recruited by the Neurodegenerative Research Group at Mayo Clinic, Rochester, MN, USA, and underwent structural and resting-state functional MRI. Spatially preprocessed data were analysed to explore the default mode network and the salience, sensorimotor, language, visual and memory networks. The data were analysed at the voxel and network levels. Bayesian hierarchical linear models adjusted for age and sex were used to analyse within- and between-network connectivity. Reduced within-network connectivity was observed in the language network in both phenotypes, with stronger evidence of reductions in logopenic progressive aphasia compared to controls. Only posterior cortical atrophy showed reduced within-network connectivity in the visual network compared to controls. Both phenotypes showed reduced within-network connectivity in the default mode and sensorimotor networks. No significant change was noted in the memory network, but a slight increase in the salience within-network connectivity was seen in both phenotypes compared to controls. Between-network analysis in posterior cortical atrophy showed evidence of reduced visual-to-language network connectivity, with reduced visual-to-salience network connectivity, compared to controls. An increase in visual-to-default mode network connectivity was noted in posterior cortical atrophy compared to controls. Between-network analysis in logopenic progressive aphasia showed evidence of reduced language-to-visual network connectivity and an increase in language-to-salience network connectivity compared to controls. Findings from the voxel-level and network-level analysis were in line with the Bayesian hierarchical linear model analysis, showing reduced connectivity in the dominant network based on diagnosis and more crosstalk between networks in general compared to controls. The atypical Alzheimer’s disease phenotypes were associated with disruptions in connectivity, both within and between brain networks. Phenotype-specific differences in connectivity patterns were noted in the visual network for posterior cortical atrophy and the language network for logopenic progressive aphasia.
MDB-35. RECURRENT MEDULLOBLASTOMA A RARE COMPLETE RESPONSE IN EXTRA NEURAL DISEASE
Schwartz, Jonathan , Weinmann, Dena, Soumen, Khatua, Keating, Gesina F. , Johnson, Heather, Neth, Bryan J.

Mayo Clinic

Neuro-Oncology | June 12, 2023 | Volume: 25 | Issue: Supplement_1 | Pages: i69-i70

10.1093/neuonc/noad073.267 Get It

Abstract Extra-neural metastasis in recurrent medulloblastoma, carries a potentially fatal outcome. No robust salvageable therapeutic strategy is present, for these clinical phenotypes. We present an 18-year male, who presented at the age of 8 years as a standard risk medulloblastoma and was treated with chemotherapy (as per ACNS0331) followed by craniospinal radiation. At first recurrence in the thoracic spine, he underwent a gross total resection of the tumor, followed by high-dose stem cell chemotherapy and focal radiation. The 2nd recurrence which occurred in the thecal sac 9 years later was treated with metronomic anti angiogenic chemotherapy with outcome a complete radiographic response. Third recurrence occurred in the liver, bone marrow, multiple bones of axial skeleton and sacrum. Molecular interrogation of the lesions showed a (non-WNT / non-SHH subtype) with absence of MYC or MYCN amplification or any other clinically significant biological aberration. He received local radiation to tumors, following which he developed severe myelosuppression. A bone marrow aspirate and biopsy showed greater than 95% involvement with medulloblastoma cells. He was treated with irinotecan and temozolomide. A dramatic response was noted after one cycle (with PET and MRI), with bone marrow involvement of less than 1%. He continues with that therapy. To-date no defined molecular profile is predictive of extra neural metastasis, and has been likened to a fatal outcome, most patients being declared for hospice care. Our patient with this unique clinical outcome, warrants extensive evaluation of these rare clinical phenotypes including methylation profiling and RNA sequencing, which might suggest, certain molecular aberrations which correlates with good response, even in these biologically aggressive variants.
Phase 1 trial of EO2463 peptide‐based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non‐Hodgkin lymphoma; EONHL1‐20/SIDNEY
Pinto, A. A., Bisneto, J. C. Villasboas, Sanz, R. García, García, Carlos Grande, Smith, Stephen D. , Wallace, D. S., Merryman, R., Marolleau, Jean Pierre, Chêne, Laurent , Fagerberg, Jan, Friedberg, Jonathan W. , Ansel, Sonam , Armand, Philippe , Pinto, A., Bosch, Francesc , Bisneto, J. C. Villasboas, Sanz, R. García, Arcaini, Luca , Marolleau, Jean‐Pierre, Filippi, Rosaria De , Bonny, Christophe , Ansel, S., Zinzani, Pier Luigi

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 581-582

10.1002/hon.3164_435 Get It

A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016
Li, H., Leonard, John P. , Kaminski, Mark , Spier, Catherine, Dakhil, Shaker R. , Smith, Sonali M. , Friedberg, Jonathan W. , Shadman, Mazyar , Rimsza, Lisa M. , Gopal, Ajay K. , LeBlanc, Michael

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 116-117

10.1002/hon.3163_79 Get It

Quick Sequential Organ Failure Assessment Score Is a Better Predictor of Septic Shock After Percutaneous Nephrolithotomy: A Secondary Analysis of Two Multicenter Prospective Trials
Gerrity, Jillian J., Berger, Jonathan , Hsi, Ryan S. , Stern, Karen , Chew, Ben H. , Nimmagadda, Naren , Kavoussi, Nicholas , Chen, Tony T., Krambeck, Amy E. , Large, Tim , Bechis, Seth K. , Monga, Manoj , Miller, Nicole L. , Lange, Dirk , Knudsen, Bodo E. , Sourial, Michael , Humphreys, Mitchell R. , Shah, Ojas , Abbott, Joel E. , Abedi, Garen , Sur, Roger L. , Chew, Ben H , Nimmagadda, Naren , Knudsen, Bodo , Abedi, Garen , Stern, Karen L , Hsi, Ryan , Miller, Nicole L , Gerrity, Jillian J., Friedlander, David Fallon

Mayo Clinic

Journal of Endourology | June 9, 2023 | Volume: 37 | Issue: 8 | Pages: 863-867

10.1089/end.2022.0677 | PMID 37294208 Get It

Diffusivity Changes in Posterior Cortical Atrophy and Logopenic Progressive Aphasia: A Longitudinal Diffusion Tensor Imaging Study
Singh, Neha Atulkumar , Graff‐Radford, Jonathan , Pham, Nha Trang Thu, Lowe, Val J. , Petersen, Ronald C. , Josephs, Keith A. , Whitwell, Jennifer L. , Singh, Neha Atulkumar , Machulda, Mary M. , Schwarz, Christopher G. , Reid, Robert I. , Jack, Clifford R.

Mayo Clinic

Journal of Alzheimer's Disease | June 9, 2023 | Volume: 94 | Issue: 2 | Pages: 709-725

10.3233/jad-221217 | PMID 37302032 Get It

Background: Posterior cortical atrophy (PCA) and logopenic progressive aphasia (LPA) are associated with characteristic patterns of structural network degeneration. Little is known about longitudinal patterns of white matter tract degeneration in these phenotypes. Objective: To assess longitudinal patterns of white matter degeneration and identify phenotype specific cross-sectional and longitudinal diffusion tensor imaging (DTI) biomarkers in PCA and LPA. Methods: Twenty-five PCA, 22 LPA and 25 cognitively unimpaired (CU) individuals were recruited and underwent structural MRI that included a DTI sequence with a follow-up one year later. Cross-sectional and longitudinal mixed effects models were fit to assess the effects of diagnosis on baseline and annualized change in regional DTI metrics. Discriminatory power was investigated using the area under the receiver operating characteristic curves (AUROC). Results: PCA and LPA showed overlapping white matter degeneration profiles predominantly in the left occipital and temporal lobes, the posterior thalamic radiation and sagittal stratum at baseline, as well as the parietal lobe longitudinally. PCA showed degeneration in the occipital and parietal white matter, cross-sectionally and longitudinally, compared to CU, while LPA showed greater degeneration in the temporal and inferior parietal white matter and the inferior fronto-occipital fasciculus cross-sectionally, and in parietal white matter longitudinally compared to CU. Cross-sectionally, integrity of the inferior occipital white matter was best able to differentiate PCA from LPA, with an AUROC of 0.82. Conclusion: These findings contribute to our understanding of white matter degeneration and support usage of DTI as a useful additional diagnostic biomarker for PCA and LPA.
Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal‐dominant Alzheimer's disease
Schultz, Stephanie A. , Shirzadi, Zahra , Liu, Lei , Fitzpatrick, Colleen , Barthélemy, Nicolas R. , Esposito, Bianca, Chen, Charles D., Goate, Alison , Berman, Sarah , Chui, Helena C., Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Gordon, Brian A. , Day, Gregory S. , Graff‐Radford, Neill R. , Hassenstab, Jason , Hanseeuw, Bernard , Hofmann, Anna, Levey, Allan I. , Xiong, Chengjie , Mori, Hiroshi , Morris, John C. , Perrin, Richard J. , Salloway, Stephen , Johnson, Keith A. , Chhatwal, Jasmeer P. , Investigators, the Dominantly Inherited Alzheimer Network, Vöglein, Jonathan , Liu, Lei , Gordon, Brian A , Day, Gregory S , Vöglein, Jonathan , Xiong, Chengjie , Chen, Charles D , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Berman, Sarah , Levey, Allan I , Schultz, Aaron P. , McDade, Eric , Renton, Alan , Joseph‐Mathurin, Nelly , Cruchaga, Carlos , Allegri, Ricardo , Benzinger, Tammie L.S. , Chui, Helena C. , Jack, Clifford R. , Jucker, Mathias , Karch, Celeste M. , Koeppe, Robert A. , Lee, Jae‐Hong , Martins, Ralph N. , Noble, James M. , Rosa-Neto, Pedro , Sánchez‐Valle, Raquel , Schofield, Peter R. , Xiong, Chengjie , Bateman, Randall J. , Sperling, Reisa Anne , Investigators, the Dominantly Inherited Alzheimer Network

Mayo Clinic

Aging Cell | June 9, 2023 | Volume: 22 | Issue: 8 | Pages: No page available

10.1111/acel.13871 | PMID 37291760 Get It

AbstractAlthough pathogenic variants in PSEN1 leading to autosomal‐dominant Alzheimer disease (ADAD) are highly penetrant, substantial interindividual variability in the rates of cognitive decline and biomarker change are observed in ADAD. We hypothesized that this interindividual variability may be associated with the location of the pathogenic variant within PSEN1. PSEN1 pathogenic variant carriers participating in the Dominantly Inherited Alzheimer Network (DIAN) observational study were grouped based on whether the underlying variant affects a transmembrane (TM) or cytoplasmic (CY) protein domain within PSEN1. CY and TM carriers and variant non‐carriers (NC) who completed clinical evaluation, multimodal neuroimaging, and lumbar puncture for collection of cerebrospinal fluid (CSF) as part of their participation in DIAN were included in this study. Linear mixed effects models were used to determine differences in clinical, cognitive, and biomarker measures between the NC, TM, and CY groups. While both the CY and TM groups were found to have similarly elevated Aβ compared to NC, TM carriers had greater cognitive impairment, smaller hippocampal volume, and elevated phosphorylated tau levels across the spectrum of pre‐symptomatic and symptomatic phases of disease as compared to CY, using both cross‐sectional and longitudinal data. As distinct portions of PSEN1 are differentially involved in APP processing by γ‐secretase and the generation of toxic β‐amyloid species, these results have important implications for understanding the pathobiology of ADAD and accounting for a substantial portion of the interindividual heterogeneity in ongoing ADAD clinical trials.